Based on the FLAURA trial, would you consider using osimertinib firstline in EGFR-mutated NSCLC?   

Yes I would. The primary reasons are that the drug is not only has better PFS but also is better tolerated and has CNS activity. There remain several questions, 1. What therapy to choose in patients who progress after front line osimertinib? 2. Does the drug only work in the 50-60% of the patients...